InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: revenue_monster post# 96963

Thursday, 09/10/2015 10:16:58 PM

Thursday, September 10, 2015 10:16:58 PM

Post# of 346491

When will we hear some response from Management? until that happens we will continue to lose 10% a day. Has anyone checked whether they are still there? the silence is deafening. we need to see some leadership here.



Rev, I think its time you re-evaluate your position, because stress does cause flipped PS you know and Peregrine has shown more leadership than any other biotech in its class.

Peregrine owns the IP 100% of PS Targeting.

Now Memorial Sloan Kettering wants PS Targeting

Now AstraZeneca wants PS Targeting

Bristol Myers Squibb even wanted PS Targeting (for free it seems lol) and yet they still collaborate.

Who is up next ? maybe we get some more hints and puzzle pieces soon

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News